Could a once-daily ADHD pill work for seniors? new study investigates

NCT ID NCT07710014

Not yet recruiting Disease control Sponsor: Dar Clinical Research Inc. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether Foquest, a once-daily extended-release methylphenidate capsule, is safe and effective for treating ADHD in adults aged 65 and older. Participants take the medication for about 10 weeks, starting at 25 mg and adjusting up to 100 mg based on response. The main goal is to see if ADHD symptoms improve, while closely monitoring heart-related safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methylphenidate hydrochloride extended-release capsules (Foquest)
What this could lead to: If successful, this could provide a safe and effective treatment option for ADHD in older adults, an age group with very limited research.
What could go wrong: This is a small, open-label study with no placebo group, so results may be biased. Older adults may be more sensitive to cardiovascular side effects like high blood pressure or heart rate changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT HYPERACTIVITY DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.